Hypothesis

Restoring CRAT activity specifically in myeloid immune cells prevents mitochondrial DNA release, suppresses cGAS‑STING‑NF‑κB driven SASP, and thereby slows organismal aging even when systemic carnitine pools remain low.

Rationale

1. Metabolic‑immune coupling – CRAT deficiency creates an acetyl‑CoA/CoA imbalance that hyperacetylates mitochondrial proteins, diminishes SIRT3 deacetylase activity, elevates ROS, and triggers mtDNA efflux into the cytosol [https://onlinelibrary.wiley.com/doi/full/10.1111/acel.14000]. This mtDNA activates cGAS‑STING, culminating in NF‑κB‑mediated SASP and chronic inflammation.
2. Cell‑type specificity – Fibroblast‑specific CRAT loss reproduces skin aging phenotypes, yet myeloid cells are the primary sensors of cytosolic DNA and major SASP producers in aged tissues. If the immune compartment is the effector of the mtDNA‑cGAS‑STING axis, rescuing CRAT there should uncouple metabolic decline from inflammatory aging.
3. Supplementation paradox – Oral L‑carnitine raises plasma carnitine and muscle fat oxidation but fails to lower circulating IL‑6, TNF‑α, or CRP in older adults [https://pmc.ncbi.nlm.nih.gov/articles/PMC5852831/]. This suggests that restoring global carnitine flux is insufficient to normalize the acetyl‑CoA/CoA ratio within immune cell mitochondria, where CRAT activity may be the limiting node.

Novel Mechanistic Insight

CRAT not only buffers acetyl groups but also sustains the NAD⁺‑dependent SIRT3 deacetylase cycle by keeping acetyl‑CoA low. In CRAT‑deficient macrophages, hyperacetylated SIRT3 substrates (e.g., SOD2, IDH2) lose activity, raising mitochondrial ROS and causing mtDNA nucleoid destabilization. Restoring CRAT re‑establishes a low acetyl‑CoA environment, reactivates SIRT3, reduces ROS, and prevents mtDNA release—thereby silencing the cGAS‑STING‑SASP circuit without requiring elevated systemic carnitine.

Testable Predictions

• Genetic test: Mice with a myeloid‑specific CRAT knock‑in (e.g., LysM‑Cre‑driven CRAT overexpression) will exhibit:

  • ↓ mitochondrial ROS and ↑ SIRT3 activity in peritoneal macrophages.
  • ↓ cytosolic mtDNA (measured by qPCR of mitochondrial genes in the cytosolic fraction).
  • ↓ STING phosphorylation, NF‑κB nuclear translocation, and SASP cytokines (IL‑1β, IL‑6, MMP3) ex vivo.
  • Improved frailty indices, grip strength, and treadmill endurance compared with wild‑type littermates fed a standard diet.
  • No significant increase in total muscle carnitine content or whole‑body fat oxidation.

• Pharmacologic test: Treating aged wild‑type mice with a cell‑permeable CRAT activator (or a SIRT3 agonist) that preferentially accumulates in phagocytes will replicate the genetic phenotype, confirming that immune‑cell‑intrinsic metabolic correction is sufficient.

• Falsification: If myeloid CRAT overexpression fails to reduce mtDNA release, SASP, or age‑related functional decline despite verified enzyme activation, the hypothesis that immune‑cell‑intrinsic CRAT drives aging would be refuted, pointing to alternative dominant pathways (e.g., inflammasome activation independent of mtDNA).

Experimental Outline

1. Generate LysM‑Cre‑CRAT^OE mice and validate CRAT overexpression in bone‑marrow‑derived macrophages.
2. Isolate macrophages from young (3 mo) and aged (24 mo) mice; measure:
   • Acetyl‑CoA/CoA ratios (LC‑MS).
   • SIRT3 activity (deacetylation of known substrates).
   • Mitochondrial ROS (MitoSOX).
   • Cytosolic mtDNA (qPCR for mt‑ND1).
   • STING‑TBK1‑IRF3 phosphorylation (Western blot).
   • SASP cytokine secretion (ELISA/Luminex).
3. Conduct longitudinal aging studies: monitor frailty, gait speed, grip strength, and survival up to 30 mo.
4. Parallel arm: administer a mitochondria‑targeted CRAT activator (e.g., conjugated to a mannose‑6‑phosphate ligand for macrophage uptake) to wild‑type aged mice and repeat immunometabolic readouts.

Impact

If confirmed, this hypothesis would reposition immune‑cell metabolic reprogramming—not systemic nutrient supplementation—as a lever to uncouple aging from its inflammatory driver. It would prioritize targeting the acetyl‑CoA/CoA rheostat within myeloid cells as a geroprotective strategy, explaining why broad carnitine supplementation has yielded limited clinical benefit while opening a precise avenue for intervention.